Abstract
The incidence of post transplant viral infections has increased with the use of more potent immunosuppressive regimens. Consequently, BK virus nephropathy (BKVN) has arisen as a significant cause of graft dysfunction and loss. Reduction of immunosuppression is the first line management of post-transplant viral infections. Other therapies such as intravenous immunoglobulin (IVIg), cidofovir, leflunomide and fluoroquinolones have been tried with varying degrees of success.
Highlights
BK virus nephropathy (BKVN) has become of significant concern as a cause of graft dysfunction and loss in the renal transplant population
We report our experience with intravenous immunoglobulin (IVIg) in three pediatric renal transplant recipients who presented with allograft dysfunction
We present a pediatric renal transplant recipient with persistent BK viremia and allograft dysfunction who responded to therapy with recovery of renal function and clearance of viremia
Summary
BK virus nephropathy (BKVN) has become of significant concern as a cause of graft dysfunction and loss in the renal transplant population. We conducted a retrospective review at the Washington University in St Louis of pediatric renal transplant recipients who received IVIg therapy for management of BKVN and report our successful treatment of BK viremia and nephropathy with immunosuppression reduction and administration of IVIg. Patients were screened for BK virus when they presented with elevations in serum creatinine. Three patients were diagnosed with BKVN and received IVIg following an inadequate response to only immunosuppression reduction.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
